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Abstract
Background: We have shown earlier that inhaled nitric oxide (iNO) administered by oxygen hood reduces pulmonary
hypertension in an animal model (J Perinatol 2002; 22:50-6). Our objective in this study was to determine feasibility of iNO
by oxygen hood in neonates with elevated alveolar-arterial oxygen gradients (A-aDO2).
Methods/Principal Findings: Masked randomized controlled pilot trial. Inclusion criteria were: gestation$34 weeks,
age,7 days, with post-ductal arterial line, and A-aDO2 400–600. Infants were randomized to study gas (iNO 20 ppm or
equivalent O2 flow) for 1 hr which was then weaned over the next 4 hours. Primary outcome was PaO2 one hour post-
randomization. Four infants each were randomized to iNO or O2 (controls). Two of the four infants given iNO had an
increase in PaO2 of .100 torr, while oxygenation was unchanged in the controls. Methemoglobinemia and other adverse
effects were not noted in any infant. Environmental levels of NO and NO2 were minimal (,1 ppm) at .0.3 m from the hood.
Conclusions: Administration of iNO by oxygen hood is feasible. Larger randomized controlled trials are required to measure
the efficacy and determine an appropriate target population for this technique.
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Introduction
Severe neonatal pulmonary hypertension affects approximately
1 in 500 term neonates [1]. Large clinical trials have shown that
inhaled nitric oxide (iNO) improves oxygenation in approximately
50% of infants who receive nitric oxide [2]. Analysis of results from
three major trials [3–5] indicates that the use of extracorporeal
membrane oxygenation (ECMO) decreased from 54% to 38% [6].
However, all controlled studies to date have studied nitric oxide
administration to neonates who are already on mechanical
ventilation. The use of iNO administered by oxygen hood has
not been systematically evaluated.
Conventionally, neonates with hypoxemia and adequate
respiratory effort are first adminstered oxygen by oxygen hood.
If oxygenation is inadequate despite a high concentration of
inspired oxygen (FiO2) or if respiratory acidosis occurs, the infant
is placed on a mechanical ventilator. If oxygenation continues to
be inadequate despite increased ventilator settings, rescue
therapies such as iNO are attempted. However, mechanical
ventilation by itself can lead to or potentiate lung injury and
predispose to chronic lung disease, and high mean airway
pressures may also decrease pulmonary blood flow and cardiac
output. It is possible that earlier administration of iNO to neonates
with abnormal gas exchange, rather than later as a rescue therapy,
might accelerate the transition of the circulation from the fetal to
neonatal physiology and improve oxygenation. This may in turn
decrease the need for mechanical ventilation and its associated
morbidity.
This study was designed as a pilot trial to evaluate the feasibility
of NO administered by hood in neonates with elevated alveolar-
arterial oxygen gradients (A-a DO2). Subsequent larger trials could
determine if this method of NO administration can decrease the
need for mechanical ventilation, ECMO, or other adverse
outcomes.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics statement: The study protocol was approved by the
Institutional Review Board of the University of Alabama at
Birmingham and parent(s) provided informed written consent
before enrollment. Enrollment was done by the principal
investigators (NA and WAC) or research coordinator (CR).
Study design and protocol: This was a masked randomized
controlled pilot trial on infants with elevated alveolar-arterial
oxygen gradients (A-aDO2) admitted to the Regional Neonatal
ICU of the University of Alabama at Birmingham, a regional
perinatal center. The ClinicalTrials.gov Identifier for this study is
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NCT00041548). The CONSORT flowchart is shown as
Figure 1. The inclusion criteria were: gestation $34 weeks at
birth; age ,7 days, post-ductal arterial line, and an A-aDO2 of
400 to 600 on two blood gases at least 30 minutes apart. After
informed consent, infants were randomized using shuffled opaque
envelopes to study gas (iNO at 20 ppm or equivalent flow of O2)
for 1 hour. The gas was then weaned hourly over the next 4 hours
(20 ppmR 10 R 5 R 2.5 R 1 R off). It was planned that if a
greater than 5% drop in oxygen saturation was observed during
weaning, the study gas would be increased to the previous
concentration and weaning would be done at 2 hourly intervals.
No weaning of FiO2 was to be done while the study gas was being
weaned. It was planned that if a greater than 5% drop in oxygen
saturation or .5% methemoglobin was observed, the study gas
would be rapidly weaned over 30 minutes and the infant would
exit the study. The iNO was introduced into an oxygen hood
(Oxydome
TM disposable hood; MaxtexH Inc.) using an INOvent
(Datex-Ohmeda), using the arrangement as shown in Figure 2.
The INOventH was prepared by performing a low range (air)
calibration and the standard pre-use procedures (leak test, system
purge, and performance test). The INOventH was connected to the
oxyhood by placing the injector module inline on the dry side of
the humidifier chamber. A minimum gas flow of 10 liters per
minute of study gas was used to avoid accumulation of nitrogen
dioxide (NO2) within the oxyhood. Monitoring of the three
inspired gas values (O2,N O 2, NO) was done by placing the end of
the sample line inside the oxyhood. Due to mixing of exhaled gases
inside the oxyhood, the ‘‘Set NO’’ was usually set 1–2 ppm higher
to achieve the desired measured NO. If the baby was randomized
to the control group, the INOmaxH cylinder was opened and used
only to pressurize the system, which prevented the ‘‘Low NO
Pressure’’ alarm. A ‘‘Masking Shield’’ covered the Display/
Control Panel and cylinder gauges, in order to maintain masking.
Only the respiratory therapist and research coordinator was aware
of the allocation assignment. Scavenging of the NO was not
Figure 1. CONSORT flowchart
doi:10.1371/journal.pone.0004312.g001
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trace amounts of NO (,1 ppm), comparable to routine use of
iNO in mechanically ventilated neonates.
The primary outcome was the PaO2 one hour after the first
hour of study gas. Secondary outcomes included: (1) A-a DO2 after
one hour of exposure to treatment gas, (2) oxygen saturation by
pulse oximetry (SpO2), (3) need for mechanical ventilation, (4)
duration of oxygen therapy, (5) methemoglobin level in post-ductal
arterial blood,* (6) Platelet count,* (7) Systemic blood pressure,*
and (8) Environmental NO and NO2 exposure* (* Safety
indicators).
The planned sample size for this study was 40, with 20 per
group (nitric oxide or oxygen). The power of the study was 85%
with n=20 in each group, a=0.05, assuming a difference in PaO2
of 25% with a standard deviation at 0.25 of mean. A non-
parametric t-test was planned to evaluate the primary outcome of
PaO2 after the first hour of study gas.
Results
Eight term or near-term (36 or more completed weeks)
appropriate for gestational age (2.5–4 kg birth weight) infants
were enrolled over a three year period (May 2002–June 2005;
Figure 1), and the study was terminated due to slow enrollment.
Enrollment was slow as most infants transferred to our regional
perinatal center for respiratory failure were already intubated
either by the referring center or by our transport team. Four
infants were white, five were female, and six were diagnosed with
idiopathic persistent pulmonary hypertension of the newborn
(PPHN), while one infant had early onset gram negative (E. coli)
sepsis, and another had meconium aspiration syndrome (Table 1).
All infants were receiving 90–95% O2 at enrollment. Four infants
were randomized to iNO and four to O2 (controls). Two of the
four infants given iNO had an increase in PaO2 of .100 torr,
while oxygenation was essentially unchanged in the controls,
although one patient had a small increase (+22 torr) (Figure 3,
Table 1). The median PaO2 after the first hour of study gas in the
infants receiving iNO was 139 torr (25
th–75
th centile: 66–215 torr)
versus 88 torr (66–114) in the infants receiving O2 (controls) (p
NS). However, the small sample size indicates that statistical
analysis would not be useful in this pilot study due to lack of
statistical power. No methemoglobinemia (all levels ,2% in both
groups), hypotension (drop in systemic blood pressure .10%),
thrombocytopenia/excessive bleeding or other adverse effects
were noted in any of the infants. No ‘‘rebound phenomenon’’ was
noted on weaning of the study gas. NO2 within the hood was less
Figure 2. Delivery of inhaled nitric oxide into an oxygen hood using an INOventH. The injector module from the INOventH is inserted into
the gas delivery circuit proximal to the humidifier (on the dry side). The sample line from the INOventH measures the oxygen concentration, nitric
oxide, and nitrogen dioxide in the oxygen hood.
doi:10.1371/journal.pone.0004312.g002
Figure 3. Change in PaO2 with study gas. Line graph showing
change in PaO2 from before initiation of study gas (nitric oxide or
oxygen) to one hour after study gas. Two of the four infants receiving
nitric oxide (dark circles connected by solid lines) had an increase in
PaO2 .100 torr, but none of the infants receiving O2 alone (open circles
connected by dashed lines) demonstrated a significant change.
doi:10.1371/journal.pone.0004312.g003
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Environmental levels of NO and NO2 were minimal (,1 ppm)
to undetectable at .0.3 m from the hood at the bedside.
Discussion
This pilot trial demonstrates the technique and feasibility of
iNO administration using an oxygen hood and a commercial iNO
delivery device. This trial had an inadequate sample size to
demonstrate efficacy or safety. However, the efficacy and safety of
iNO in intubated infants is already known [2–6], and the purpose
of this pilot trial was to show if iNO could be administered into an
oxygen hood in the clinical setting. Two of the four infants who
received iNO had an increase in PaO2 .100 torr, while none of
the infants in the oxygen control groups had a similar increase.
Neonates with hypoxemia (PaO2 ,50 torr) or respiratory acidosis
while on 100% oxygen at the onset are usually intubated and
mechanically ventilated. The A-a DO2 usually is .600 torr in this
situation, and often more than 630 torr, depending on the PaCO2.
However, neonates who present with markedly elevated A-a DO2
(.400 torr) but with adequate oxygenation (PaO2 50–150 torr on
FiO2 $0.95), respiratory effort, and acid-base status often present
a dilemma – to intubate and mechanically ventilate or not? These
neonates with either a severe V/Q mismatch (intra-pulmonary
shunt) or right to left shunts (extra-pulmonary shunt) (frequently
both mechanisms may be operative to a variable degree) are often
maintained on high oxygen concentrations (FiO2 .0.7) delivered
by oxygen hood, in an attempt to maintain adequate oxygenation
and possibly accelerate the spontaneous resolution of elevated
pulmonary pressures and minimize the risk of hypoxic pulmonary
vasoconstriction or V/Q mismatch without resorting to mechan-
ical ventilation. While some of these neonates improve spontane-
ously, others persist with high A-a DO2 and ultimately require
mechanical ventilation and occasionally ECMO. It is possible that
these infants may benefit from iNO by oxygen hood.
Since the observation that iNO can cause selective pulmonary
vasodilation in neonates [7,8], multiple randomized controlled
trials [3–6] have been performed and a systematic review indicates
that iNO may benefit neonates with hypoxemic respiratory failure
[2]. The majority of the available literature as briefly described
above deals with neonates on mechanical ventilation, since NO
has been used so far as a ‘‘rescue’’ therapy for infants not
responding to conventional, and in some cases, high frequency
ventilation. The current practice of intubation and mechanical
ventilation of the majority of infants with hypoxemic respiratory
failure makes it difficult to evaluate non-invasive methods of iNO
delivery such as by oxygen hood. iNO has also been delivered by
nasopharyngeal tube [9], pulsed nasal cannula, and face mask
[10]. However, due to entrainment of room air and varying
contributions from mouth breathing, the actual delivered NO level
by nasal or nasopharyngeal cannulae cannot be ascertained with
accuracy. Especially during weaning, it is important that the iNO
be reduced gradually and carefully controlled in order to avoid
rebound pulmonary hypertension. The delivered oxygen and iNO
concentrations may possibly be regulated better with the oxygen
hood than with the nasal cannulae. The other problem with nasal
cannulae is that the presence of a nasal prong(s) will partially
occlude the nostrils and increase airway resistance significantly,
further compromising respiratory effort and oxygenation in a
neonate with abnormal gas exchange.
A major proportion of morbidity and mortality in term neonates
is due to hypoxemic respiratory failure. Fortunately, the incidence
of hypoxic respiratory failure in newborn infants has decreased in
recent years, but this has led to poor accrual for clinical trials on
PPHN [11]. A limitation of our pilot trial in a regional perinatal
center is that many potential subjects were transported already
intubated. Randomized multi-center clinical trials involving large
delivery centers are required to determine if non-invasive
administration of iNO into an oxygen hood decreases the need
for mechanical ventilation and subsequent need for ECMO in this
population, and if this improved short-term outcome results in a
lower mortality, earlier discharge and both direct and indirect cost
savings.
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Table 1. Characteristics of neonates enrolled in the trial, and their response to the study gas.
Group Diagnosis
Initial
A-aDO2
Final
A-aDO2
Initial PaO2
(torr)
Final
PaO2
(torr)
Change
in PaO2
Pre-trial
O2
Post-trial
O2
Need
for IMV
Length of
Stay (days)
O2-1 Sepsis 492 479 102 124 +22 2 days 4 days No 14
O2-2 PPHN 586 587 75 72 23 2 days 4 days No 7
O2-3 PPHN 551 568 122 104 218 2 days 11 days Yes 26
O2-4 PPHN 580 581 61 59 22 20 h 4 days Yes 10
NO-1 Mec Asp 564 428 64 200 +136 5 h 24 h No 5
NO-2 PPHN 561 575 97 78 219 24 h 9 days Yes 12
NO-3 PPHN 554 585 54 53 21 4 h 6 days No 14
NO-4 PPHN 523 422 127 229 +102 33 h 6 days Yes 14
doi:10.1371/journal.pone.0004312.t001
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